 GARDEN CITY, New York, June 14, 2022 GLOBE NEWSWIRE -- Beyond Air, Inc. NASDAQ: XAIR, a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide NO for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide UNO for the treatment of solid tumors, today announced that it has rescheduled the reporting of the financial results for its fiscal fourth quarter and year ended March 31, 2022 to Tuesday, June 28, 2022. The Companys management team will also host its quarterly conference call and webcast at 4:30 pm Eastern Time on June 28th. 